Saturday 17 October 2026 Export TNYA’s income statement to Excel — free account

Tenaya Therapeutics, Inc.

In the quarter to June 2026, EPS fell 42.9% and free cash flow grew 76.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

0.37 0.04 −9.76%

Follow TNYA

Alert me

Market cap: $91.6M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 5.98

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	—	—	6	—	—	3	—	—	2	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 91.57

Revenue —

Net Income (103.11)

Free Cash Flow (52.59)

Net Debt (78.08)

Current Ratio 4.52

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.16

Past 5Y EPS Growth —

This Y EPS Growth 18.64%

Next Y EPS Growth 23.75%

Next Y revenue growth —

Next 5Y EPS Growth 82.11%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 43.65%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	105	61	101	78
Receivables	—	—	—	0
Inventory	—	—	—	—
Other	—	—	—	—
	112	67	106	86

	2023	2024	2025	Q'26
Payables	6	5	4	3
ST’ Debt	—	—	—	—
Other	—	—	—	6
	23	16	15	19

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(2.44%)	(20.29%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(4)	—	—	—
’25	(23)	(16)	(16)	(14)	(68)
’24	(29)	(24)	(20)	(18)	(91)
’23	(30)	(26)	(24)	(22)	(102)
’22	(29)	(25)	(28)	(23)	(104)
’21	(16)	(12)	(17)	(16)	(61)
’20	(8)	(7)	(10)	(10)	(35)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(4)	—	—	—
’25	(23)	(16)	(16)	(14)	(69)
’24	(29)	(24)	(20)	(19)	(92)
’23	(31)	(26)	(24)	(22)	(103)
’22	(37)	(33)	(32)	(23)	(125)
’21	(20)	(15)	(22)	(29)	(86)
’20	(9)	(8)	(10)	(19)	(45)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	(0.20)	—	—	—
’25	(0.24)	(0.14)	(0.12)	(0.12)	(0.59)
’24	(0.40)	(0.34)	(0.30)	(0.28)	(1.31)
’23	(0.43)	(0.45)	(0.39)	(0.40)	(1.68)
’22	(0.75)	(0.69)	(0.74)	(0.61)	(2.76)
’21	(11.93)	(13.26)	(0.68)	(0.63)	(4.10)
’20	(10.15)	(9.21)	(10.29)	(9.85)	(39.50)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	15.35	1.64	1.66	0.99	0.36	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	32.00	19.45	8.09	7.01	2.35
People
People	Employees	—	—	—	—	85	106	141	140	97	70
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	—	—	(26)	(38)	(73)	(124)	(124)	(111)	(91)
	EBT margin, %	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	(26)	(38)	(73)	(124)	(124)	(111)	(91)
	Depreciation	—	—	—	2	2	3	6	9	8	9
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(34.70)	(39.50)	(4.10)	(2.76)	(1.68)	(1.31)	(0.59)
	Cash flow	—	—	—	(31.87)	(36.47)	(3.43)	(2.33)	(1.38)	(1.07)	(0.45)
	Capex	—	—	—	(3.87)	(10.04)	(1.42)	(0.46)	(0.02)	(0.01)	0.00
	Free cash flow	—	—	—	(35.74)	(46.51)	(4.85)	(2.79)	(1.40)	(1.08)	(0.45)
	Book value	—	—	—	38.76	143.46	15.71	5.43	1.89	1.09	0.81
	Shares, m	—	—	—	1	1	18	45	74	85	153
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(24)	(35)	(61)	(104)	(102)	(91)	(68)
	Capex	—	—	—	(3)	(10)	(25)	(21)	(1)	(1)	(1)
	Free cash flow	—	—	—	(27)	(45)	(86)	(125)	(103)	(92)	(69)
Balance, $m
Balance, $m	Working capital	—	—	—	24	125	234	170	89	51	90
	Total debt	—	—	—	—	—	16	15	—	—	—
	Net debt	—	—	—	(27)	(129)	(251)	(187)	(105)	(61)	(101)
	Shareholders’ equity	—	—	—	29	139	279	243	139	93	123
Returns, %
Returns, %	ROA	—	—	—	(138.05)	(41.25)	(31.46)	(41.70)	(55.21)	(76.52)	(67.90)
	ROIC	—	—	—	(646.75)	(223.04)	(167.13)	(138.11)	(235.74)	(230.73)	(256.77)
	ROE	—	—	—	42.01	61.41	(73.75)	(47.39)	(64.83)	(95.69)	(83.84)

Negative figures in brackets.

All 10 years →

Latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%	Compare
ATRA Atara Biotherapeutics, Inc.	$96.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)	Compare
ANIX ANIXA BIOSCIENCES INC	$96.7M	— (loss-making)	— (loss-making)	0.00%	n/m	−17.14% (below 0%: shrinking)	0.00%	0.00%	Compare
ICCC ImmuCell Corporation	$95.9M	126×	— (loss-making)	+11.50% (above 0%: growing)	+233.33% (above 0%: growing)	+54.86% (above 0%: growing)	33.92%	26.93%	Compare
RANI Rani Therapeutics Holdings, Inc.	$94.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−55.29% (below 0%: shrinking)	100.00%	(516.86%)	Compare
VXRT VAXART, INC.	$92.4M	2.8×	2.1×	−31.58% (below 0%: shrinking)	n/m	+117.38% (above 0%: growing)	100.00%	(48.45%)	Compare
TNYA Tenaya Therapeutics, Inc.	$91.6M	— (loss-making)	—	—	n/m	+76.45% (above 0%: growing)	100.00%	(3,971.89%)
RLYB Rallybio Corporation	$89.1M	2.0×	— (loss-making)	0.00%	n/m	+648.02% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$96.3M	2.8×	—	0.00%	—	+40.93%	77.77%	(24.22%)

All 614 Biotechnology stocks →